Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Active Lupus Nephritis
NCT04376827Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of guselkumab in lupus nephritis (LN), sponsored by Janssen Pharmaceutical. Started Sep 2020; status: terminated.
02
Drugs
guselkumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04376827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376827.